INMB
INmune Bio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$32.97M
P/E Ratio
—
EPS
$-1.63
Beta
1.01
52W High
$8.05
52W Low
$1.09
50-Day MA
$1.38
200-Day MA
$1.59
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About INmune Bio Inc
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-30.79M |
| Operating Margin | 0.00% |
| Return on Equity | -168.80% |
| Return on Assets | -52.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.74 |
| Price-to-Book | 1.70 |
| Price-to-Sales (TTM) | 760.34 |
| EV/Revenue | 286.0 |
| EV/EBITDA | -5.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 257.10% |
| Shares Outstanding | $26.59M |
| Float | $22.16M |
| % Insiders | 11.16% |
| % Institutions | 19.70% |
Historical Volatility
HV 10-Day
60.58%
HV 20-Day
54.78%
HV 30-Day
73.21%
HV 60-Day
73.97%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($7.00 target)
1
Strong Buy3
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026